BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38583454)

  • 1. Feasibility, safety, and impact of the RTS,S/AS01
    Asante KP; Mathanga DP; Milligan P; Akech S; Oduro A; Mwapasa V; Moore KA; Kwambai TK; Hamel MJ; Gyan T; Westercamp N; Kapito-Tembo A; Njuguna P; Ansong D; Kariuki S; Mvalo T; Snell P; Schellenberg D; Welega P; Otieno L; Chimala A; Afari EA; Bejon P; Maleta K; Agbenyega T; Snow RW; Zulu M; Chinkhumba J; Samuels AM;
    Lancet; 2024 Apr; 403(10437):1660-1670. PubMed ID: 38583454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01
    RTS,S Epidemiology EPI-MAL-002 Study Group
    Malar J; 2021 Apr; 20(1):197. PubMed ID: 33902599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of RTS,S/AS01
    Samuels AM; Ansong D; Kariuki SK; Adjei S; Bollaerts A; Ockenhouse C; Westercamp N; Lee CK; Schuerman L; Bii DK; Osei-Tutu L; Oneko M; Lievens M; Attobrah Sarfo MA; Atieno C; Morelle D; Bakari A; Sang T; Jongert E; Kotoh-Mortty MF; Otieno K; Roman F; Buabeng PBY; Ntiamoah Y; Ofori-Anyinam O; Agbenyega T;
    Lancet Infect Dis; 2022 Sep; 22(9):1329-1342. PubMed ID: 35753316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
    Hogan AB; Winskill P; Ghani AC
    PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the safety, impact and effectiveness of RTS,S/AS01
    Praet N; Asante KP; Bozonnat MC; Akité EJ; Ansah PO; Baril L; Boahen O; Mendoza YG; Haine V; Kariuki S; Lamy M; Maleta K; Mungwira R; Ndeketa L; Oduro A; Ogutu B; Olewe F; Oneko M; Orsini M; Roman F; Bahmanyar ER; Rosillon D; Schuerman L; Sing'oei V; Terlouw DJ; Wéry S; Otieno W; Pirçon JY
    Malar J; 2022 Apr; 21(1):132. PubMed ID: 35468801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
    Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
    Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
    Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
    BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal vaccination with RTS,S/AS01
    Dicko A; Ouedraogo JB; Zongo I; Sagara I; Cairns M; Yerbanga RS; Issiaka D; Zoungrana C; Sidibe Y; Tapily A; Nikièma F; Sompougdou F; Sanogo K; Kaya M; Yalcouye H; Dicko OM; Diarra M; Diarra K; Thera I; Haro A; Sienou AA; Traore S; Mahamar A; Dolo A; Kuepfer I; Snell P; Grant J; Webster J; Milligan P; Lee C; Ockenhouse C; Ofori-Anyinam O; Tinto H; Djimde A; Chandramohan D; Greenwood B
    Lancet Infect Dis; 2024 Jan; 24(1):75-86. PubMed ID: 37625434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M
    Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
    Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
    PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
    Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
    Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
    Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
    BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
    Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
    PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of malaria vaccine uptake among children 6-24 months in the Kassena Nankana Municipality in the Upper East Region of Ghana.
    Yeboah D; Owusu-Marfo J; Agyeman YN
    Malar J; 2022 Nov; 21(1):339. PubMed ID: 36384655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
    Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
    Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
    RTS,S Clinical Trials Partnership
    Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.